{"schema_version":"secwatch.filing_event.v1","accession":"0001808665-23-000028","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.705063+00:00","generated_at":"2026-06-15T09:45:46.865536+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Assertio Q1 sales +18% to $41.8M; raises FY2023 outlook; plans Spectrum acquisition in Q3","bullets":["Q1 net product sales $41.8M, up 18% YoY; GAAP net loss of $3.5M vs net income of $9.1M a year ago.","Adjusted EBITDA $25.6M vs $23.9M YoY; adjusted EPS $0.29 vs $0.38.","Full-year net product sales guidance raised to $157-167M; adjusted EBITDA guidance raised to $90-98M.","Acquisition of Spectrum (all-stock + CVR) expected to close Q3 2023, accretive to adjusted EPS and cash flow in 2024.","Converted $30M of convertible debt in Feb 2023, reducing outstanding debt by 43% and saving $2M annual interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001808665-23-000028","json":"https://secwatch.observer/filing/0001808665-23-000028.json","markdown":"https://secwatch.observer/filing/0001808665-23-000028.md","text":"https://secwatch.observer/filing/0001808665-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000180866523000028/0001808665-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000180866523000028/asrt-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:45:46.865536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7fea4ea1fd7ae411d4abdd11fe41b775bb6fe7d9","claim":"Assertio Holdings, Inc. reported the three months ended March 31, 2023 results: revenue $41.8 million, net income $(3.5) million, EPS $(0.07) per share. Guidance raised.","evidence_excerpt":"Adjusted Earnings Per Share (Non-GAAP) 1 $ 0.29 $ 0.38 First quarter results included the following as compared to the prior year quarter: • Net product sales increased 18%, to $41.8 million. ◦ Increased sales of Indocin and the addition of Sympazan more than offset expected declines in Cambia and Zipsor. ◦ Indocin sales increased 42%, primarily due to the transition","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808665/000180866523000028/0001808665-23-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$41.8 million"},{"label":"Net income","value":"$(3.5) million"},{"label":"EPS","value":"$(0.07) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}